Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
Cathie Wood's Ark Innovation ETF added Intellia Therapeutics (gene-editing) and Recursion Pharmaceuticals (AI-driven drug development) to its portfolio, highlighting their potential despite risks.
AI in Life Sciences Market Poised for Explosive Growth with 27.9% CAGR Through 2029
AI in Life Sciences Market to grow from $9.8B in 2024 to $33.5B by 2029, at a CAGR of 27.9%, driven by AI-driven drug discovery and personalized medicine.
Revolutionizing clinical trials: the role of AI in accelerating drug development
AI revolutionizes clinical trials by enhancing data collection, patient recruitment, and analysis, reducing time and costs. It enables personalized medicine, improves efficiency, and accelerates drug development. Despite challenges like data quality and ethical concerns, AI's potential in clinical trials is transformative, promising faster, more accurate outcomes.
The State of AI in Drug Discovery 2024
AI and machine learning are revolutionizing drug discovery in biotech and pharma. GEN’s virtual summit on October 30th features keynotes by David Baker, Najat Khan, and others, discussing latest advances, challenges, and business landscape of AI in drug discovery. Registration is free.
The Week in AI: 'Safe' Superintelligence and Human Authentication
OpenAI co-founder Ilya Sutskever's new venture, Safe Superintelligence (SSI), secures $1 billion for 'safe' superintelligence. AI-driven drug discovery faces challenges in clinical trials, while tech giants race to perfect multilingual chatbots. Researchers unveil 'personhood credentials' to distinguish humans from AI online.
AI Drug Discovery Trial Reveals Promise and Challenges of Using the Tech
AI's potential in drug discovery is highlighted by Recursion Pharmaceuticals' Phase 2 SYCAMORE trial for REC-994, targeting cerebral cavernous malformation, which met safety endpoints but showed mixed efficacy. Despite AI's ability to analyze vast datasets, challenges include data scarcity for rare conditions and predicting drug efficacy accurately. Experts suggest developing more complex AI models and combining AI with traditional techniques to advance drug discovery.
Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition
Recursion Pharmaceuticals announced successful results for its lead drug candidate REC-994, showing it safe and tolerable for cerebral cavernous malformation patients in a Phase 2 study, though likely not satisfying investors closely watching the AI drug developer.
Recursion announces positive phase 2 trial results for CCM drug
Recursion announced Phase 2 SYCAMORE trial results for REC-994, a CCM treatment, showing safety and promising MRI-based efficacy at the highest dose. The study, involving 62 participants, met primary safety endpoints but lacked significant patient-reported improvements. Recursion plans further FDA discussions and data publication. CCM affects 360,000 in the US and EU5, with Recursion leveraging its Recursion OS for drug development.
AI in Pharma and Biotech Market Projected Growth at 18.8% CAGR to Reach USD 13.1 billion by 2034
The global AI in pharma and biotech market, valued at US$ 1.8 billion in 2023, is projected to reach US$ 13.1 billion by 2034, growing at a CAGR of 18.8%. AI transforms drug discovery by speeding up the process, reducing costs, and enhancing precision medicine through advanced data analytics and machine learning. North America leads in AI-driven biotech, with significant contributions from research institutions and tech companies.
© Copyright 2025. All Rights Reserved by MedPath